Business Context and Reporting Period
Company: Hercules Technology Growth Capital, Inc. (Hercules)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2012
Hercules is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC) and taxed as a Regulated Investment Company (RIC). The company focuses on providing senior secured loans to venture capital-backed companies in technology-related markets, including biotechnology, life sciences, and clean technology. As of September 30, 2012, the company held 52,884,820 shares of common stock outstanding.
Key Financial Metrics
| Metric | Amount (in thousands) |
|---|---|
| Total Assets | $909,513 |
| Total Investments (at value) | $774,459 |
| Cash and Cash Equivalents | $107,093 |
| Total Liabilities | $440,396 |
| Total Net Assets | $469,117 |
| Net Asset Value (NAV) per Share | $9.42 |
| Net Investment Income (9 months) | $35,036 |
| Net Realized Gains (9 months) | $2,049 |
| Net Unrealized Depreciation (9 months) | $(15,187) |
| Net Increase in Net Assets from Operations (9 months) | $21,898 |
Material Changes vs. Prior Period
- Portfolio Growth: Total investment portfolio value increased to $774.5 million from $652.9 million at December 31, 2011. This growth was driven by new fundings of approximately $268.3 million and restructure fundings of $46.7 million.
- Realized Losses: The company recognized net realized losses of approximately $9.1 million for the quarter ended September 30, 2012, primarily due to the liquidation of MaxVision Holding, L.L.C. ($8.7 million loss), Zeta Interactive Corporation, and Magi.com. For the nine-month period, net realized gains were $2.0 million.
- Unrealized Depreciation: Significant net unrealized depreciation of $15.2 million was recorded for the nine-month period, largely attributed to $14.0 million in depreciation on debt investments related to market interest rate fluctuations and collateral-based impairments.
- Debt Issuance: The company significantly increased its debt capacity and outstanding borrowings. It issued $84.5 million in April 2019 Notes and $75.0 million in September 2019 Notes during the period. Total outstanding borrowings increased to $430.9 million from $305.5 million at year-end 2011.
- Operating Expenses: Operating expenses for the nine months ended September 30, 2012, totaled $35.1 million, an increase from $29.9 million in the prior year period, driven by higher interest and fee expenses on new debt issuances.
Guidance, Outlook, and Risks
- Dividend Policy: The Board declared a quarterly cash dividend of $0.24 per share on October 26, 2012, payable November 21, 2012. The company aims to distribute approximately 90-100% of its taxable quarterly income.
- Liquidity and Capital: The company maintains significant liquidity with $107.1 million in cash and $150.0 million in available credit facilities (Wells and Union Bank) with no outstanding balances as of September 30, 2012. It also has $225.0 million in SBA debenture capacity, of which $200.25 million is outstanding.
- Portfolio Grading: The weighted average investment grading of the debt portfolio increased slightly to 2.12 (on a scale of 1-5, where 1 is highest quality) from 2.01 at year-end 2011. One portfolio company was on non-accrual status with a fair value of zero.
- Subsequent Events: In October 2012, the company completed a follow-on public offering of 3.1 million shares for approximately $33.6 million. Additionally, portfolio company NextWave Pharmaceuticals reached a definitive agreement to be acquired by Pfizer Inc. for $255 million plus potential milestones.
- Risks: Key risks include the impact of interest rate fluctuations on net investment income, the ability to access capital markets, and the valuation uncertainty of Level 3 assets (private debt and equity) which comprise the majority of the portfolio.
Investor Verification Checklist
- Debt Servicing: Verify the company's ability to service its increased debt load ($430.9 million outstanding) given the rise in interest expense and the reliance on variable-rate assets to match liabilities.
- Valuation Methodology: Review the Board's fair value determinations for Level 3 assets, particularly the $14.0 million unrealized depreciation on debt investments, to understand the sensitivity to hypothetical market yield inputs.
- Portfolio Concentration: Assess the concentration risk in the top ten portfolio companies, which represented 36.2% of the total portfolio fair value as of September 30, 2012.
- Realized Losses: Monitor the impact of the liquidation of MaxVision Holding, L.L.C. and other distressed assets on future earnings and NAV.
- Dividend Sustainability: Confirm that taxable income continues to support the $0.24 per share quarterly dividend, noting that a portion of distributions may be a return of capital if taxable earnings fall short.